Platelets in atherothrombosis

Mayo Clinic Proceedings

Volumn 81, Issue 1, 2006, Pages 59-68

  Vorchheimer, David A ^a   Becker, Richard ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; METOPROLOL; PRASUGREL; THIENO[3,2 C]PYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN;

ANGINA PECTORIS; ARTERY OCCLUSION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATHEROTHROMBOSIS; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL SECRETION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; INFLAMMATION; INTESTINE ULCER; REVIEW; STROKE; THROMBOCYTE; THROMBOGENESIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

EID: 30144446003     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.1.59     Document Type: Review

References (89)

1. Fuster V, Gotto AM, Libby P, Loscalzo J, McGill HC. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events, Task Force 1: pathogenesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol. 1996;27:964-976.
2. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
3. Fuster V, Lewis A. Conner Memorial Lecture: mechanisms leading to myocardial infarction: insights from studies of vascular biology [published correction appears in Circulation. 1995;91:256]. Circulation. 1994;90:2126-2146.
4. Munger MA, Hawkins DW. Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc (Wash DC). 2004;44(2, suppl 1):S5-S12.
5. Pasterkamp G, Falk E. Atherosclerotic plaque rupture: an overview. J Clin Basic Cardiol. 2000;3:81-86.
6. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs. 2002;1:273-288.
7. Ferguson JJ, Quinn M, Moake JL. The physiology of normal platelet function. In: Ferguson JJ III, Chronos NAF, Harrington RA, eds. Antiplatelet Therapy in Clinical Practice. London, England: Martin Dunitz; 2000:15-34.
8. Samara WM, Gurbel PA. The role of platelet receptors and adhesion molecules in coronary artery disease. Coron Artery Dis. 2003;14:65-79.
9. Kuwahara M, Sugimoto M, Tsuji S, et al. Platelet shape changes and adhesion under high shear flow. Arterioscler Thromb Vasc Biol. 2002;22:329-334.
10. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: implications for therapy. Anesthesiology. 2004;100:722-730.
11. Cimminiello C, Toschi V. Atherothrombosis: the role of platelets. Eur Heart J Suppl. 1999;1(A):A8-A13.
12. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall: experimental study in the pig model. J Clin Invest. 1989;84:1134-1144.
13. Lassila R, Badimon JJ, Vallabhajosula S, Badimon L. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood: effects of different stenoses on thrombus growth. Arteriosclerosis. 1990;10:306-315.
14. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599.
15. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-1569.
16. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (first of two parts). N Engl J Med. 1992;326:242-250.
17. Badimon JJ, Zaman A, Helft G, Fayad Z, Fuster V. Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost. 1999;82:997-1004.
18. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:1549-1554.
19. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
20. Folsom AR, Rosamond WD, Shahar E, et al. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation. 1999;100:736-742.
21. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
22. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost. 2003;1:1897-1905.
23. Nassar T, Sachais BS, Akkawi S, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem. 2003;278:6187-6193.
24. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61-67.
25. von Hundelshausen P, Weber KS, Huo Y, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation. 2001;103:1772-1777.
26. Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-α secretion: signal integration and NF-κB translocation. J Clin Invest. 1995;95:2297-2303.
27. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996;97:1525-1534.
28. Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet. 1997;349:490-495.
29. Cha J-K, Jeong M-H, Bae H-R, et al. Activated platelets induce secretion of interleukin-1β, monocyte chemotactic protein-1, and macrophage inflammatory protein-1α and surface expression of intercellular adhesion molecule-1 on cultured endothelial cells. J Korean Med Sci. 2000;15:273-278.
30. Imaizumi T, Albertine KH, Jicha DL, McIntyre TM, Prescott SM, Zimmerman GA. Human endothelial cells synthesize ENA-78: relationship to IL-8 and to signaling of PMN adhesion. Am J Respir Cell Mol Biol. 1997;17:181-192.
31. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 2001;12:74-82.
32. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 2002;106:981-986.
33. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
34. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost. 1998;80:1008-1014.
35. Zimmerman GA. Two by two: the pairings of P-selectin and P-selectin glycoprotein ligand 1. Proc Natl Acad Sci U S A. 2001;98:10023-10024.
36. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001;86:746-756.
37. Ramos CL, Huo Y, Jung U, et al. Direct demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice. Circ Res. 1999;84:1237-1244.
38. Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart. 2003;89:993-997.
39. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003;23:2131-2137.
40. Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med. 2004;14:18-22.
41. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491-495.
42. Hillis GS, Terregino C, Taggart P, et al. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. Am Heart J. 2002;143:235-241.
43. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614-620.
44. Schafer AI. Antiplatelet therapy. Am J Med. 1996;101:199-209.
45. Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1988;318:262-264.
46. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977;8:301-314.
47. Sorensen PS, Pedersen H, Marquardsen J, et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks: a Danish cooperative study. Stroke. 1983;14:15-22.
48. High-dose acetylsalicylic acid after cerebral infarction: a Swedish Cooperative Study. Stroke. 1987;18:325-334.
49. Boysen G, Sorensen PS, Juhler M, et al. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke. 1988;19:1211-1215.
50. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
51. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
52. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-830.
53. Nyman I, Larsson H, Wallentin L, Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. Lancet. 1992;340:497-501.
54. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients [published correction appears in BMJ. 1994;308:1540]. BMJ. 1994;308:81-106.
55. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R, ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ. 1998;316:1337-1343.
56. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease [published correction appears in Chest. 2001;120:1427]. Chest. 2001;119(1, suppl.):228S-252S.
57. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002;324:141]. BMJ. 2002;324:71-86.
58. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25:2331-2336.
59. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-172.
60. Alimento M, Campodonico J, Santambrogio G, et al. The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors [in Italian]. Cardiologia. 1997;42:605-610.
61. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419-425.
62. Heptinstall S, May JA, Glenn JR, Sanderson HM, Dickinson JP, Wilcox RG. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haemost. 1995;74:1310-1315.
63. Klinkhardt U, Graff J, Harder S. Clopidogrel, but notabciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther. 2002;71:176-185.
64. Orford JL, Kinlay S, Adams MR, Simon DI, Selwyn AP. Clopidogrel inhibits shear-induced platelet function. Platelets. 2002;13:187-189.
65. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005;31:184-194.
66. Balsano F, Rizzon P, Violi F, et al, Studio della Ticlopidina nell'Angina Instabile Group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation. 1990;82:17-26.
67. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicentre Study [published correction appears in J Intern Med. 1990;228:659]. J Intern Med. 1990;227:301-308.
68. Becquemin J-P, Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med. 1997;337:1726-1731.
69. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA. 2004;292:1867-1874.
70. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
71. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001;345:1506 and 1716]. N Engl J Med. 2001;345:494-502.
72. Steinhubl SR, Berger PB, Mann JT III, et al, CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in JAMA. 2003;289:987]. JAMA. 2002;288:2411-2420.
73. Diener HC, Bogousslavsky J, Brass LM, et al, MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
74. Sabatine MS, Cannon CP, Gibson CM, et al, CLARITY-TIMI28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
75. Chen Z. Randomized, placebo-controlled trial of adding clopidogrel to aspirin in 46,000 acute myocardial infarction patients (COMMIT/CCS-2- Clopidogrel). Presented at: American College of Cardiology Annual Scientific Session; Orlando, Fla; March 6-9, 2005. Available at: www.acc05online.acc .org/highlights/keyLectures.aspx?sessionId=7989&&date=9. Accessibility verified November 29, 2005.
76. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials [published correction appears in Lancet. 2002;359:2120]. Lancet. 2002;359:189-198.
77. Chew DP, Bhatt DL. Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials. Intern Med J. 2002;32:338-345.
78. Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Crit Care Med. 2002;30(5, suppl.):S332-S340.
79. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-1374.
80. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA. 1999;281:1407-1414.
81. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study [published correction appears in Lancet. 1997;350:744]. Lancet. 1997;349:1429-1435.
82. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [published correction appears in N Engl J Med. 1998;339:415]. N Engl J Med. 1998;338:1488-1497.
83. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
84. Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045-2048.
85. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
86. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-1924.
87. White HD. Non-ST-elevation acute coronary syndromes: unstable angina and non-ST-elevation myocardial infarction. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:351-384.
88. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201-206.
89. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15-28.